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Current Status of Human Papillomavirus Vaccines
Barbara Ma,1 Richard Roden,1 T.-C. Wu1–4*
Cervical cancer is the second leading cause of can-
cer deaths in women worldwide, with ∼500,000
diagnoses and 274,000 deaths annually. It remains
a significant source of morbidity and mortality de-
spite effective screening tools and treatments for
its precursor: high-grade cervical intraepithelial
neoplasia (CIN). Increased understanding of cer-
vical pathogenesis has led to the identification of
human papillomavirus (HPV) as the etiological
agent for cervical cancer, and the development of
preventive and therapeutic vaccines that target
HPV antigens for the control of cervical cancer.
Here, we discuss the current status of HPV vaccines.
Currently Approved Prophylactic 
HPV Vaccines
The commercialization of two prophylactic HPV
vaccines, Gardasil (Merck, Whitehouse Station, NJ,
USA) and Cervarix (GlaxoSmithKline, Brentford,
Middlesex, UK), represents a milestone for the pre-
vention of cervical cancer.1 The vaccines target the
HPV L1 major capsid protein, which can assemble
to form virus like particles (VLPs) that resemble
native virions morphologically, to generate robust
antibody responses and prevent HPV infection.
Gardasil contains VLPs for HPV-16 and HPV-18,
which are associated with cervical cancer and VLPs
for HPV-6 and HPV-11, which are associated with
benign genital warts. Cervarix contains only HPV-
16 and HPV-18 VLPs. Although both vaccines con-
tain classical aluminum salt adjuvants, Cervarix
also contains monophosphoryl lipid A, a Toll-like
receptor 4 agonist that primes innate immunity
and can stimulate adaptive immunity for enhanced
antibody titers. The United States Food and Drug
Administration approved Gardasil in 2006 for
women aged 9–26 years. In October 2009, it ap-
proved Cervarix for use in women aged 10–25
years, and approved Gardasil for use in men aged
9–26 years to prevent genital warts and the spread
of cervical cancer. These recent events could have
a further impact on cervical cancer rates.
Issues Faced by Current Preventive 
HPV Vaccines
Although current preventive HPV vaccines are
promising for global prevention of cervical cancer,
there are some remaining issues.
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Cost
The high cost, the need for refrigeration and mul-
tiple doses of the commercial preventive HPV vac-
cines preclude their widespread implementation
in developing countries, which have more than
80% of cervical cancer cases. Gardasil and Cervarix
each require three doses that cost ≥US$100/dose.
For low-income countries, the per dose cost would
need to be less than US$5 for vaccination to be af-
fordable.2 Employment of basic structural units
of the HPV capsid assembled from five L1 mono-
mers, termed L1 capsomers, represents a potential
alternative because they are more thermostable
and cheaper to produce than VLPs. L1 capsomers
produced in Escherichia coli3 and expression of
L1 in recombinant Salmonella enterica serovars.
Typhimurium4 have been shown to induce pro-
tective antibodies in preclinical models. Other op-
tions include needle free administration routes
to lower complexity and vaccination cost.
Duration of vaccine efficacy
Duration of HPV vaccine efficacy is crucial in 
deciding whether cervical cancer is merely post-
poned or truly prevented. Analyses have indi-
cated that duration must last at least 15 years for
cost-effective prevention of cervical cancer.1 Al-
though Cervarix and Gardasil are highly effica-
cious in preventing HPV-16/18-associated lesions,
the duration of efficacy beyond 6.4 years for
Cervarix and 5 years for Gardasil is unknown. In
a head-to-head trial, Cervarix was shown to have
somewhat higher antibody titers for HPV-16 and
HPV-18 than did Gardasil, but it is unclear if this
will translate into a more durable response.5 It
will be important to follow up on these vaccines
to see if two doses are sufficient, or if additional
booster shots are required.
Coverage of HPV types
Gardasil and Cervarix contain VLPs for HPV-16
and HPV-18, which account for up to 75% of cer-
vical cancers, with more than 10 HPV types ac-
counting for the remaining cases. Unfortunately,
these vaccine elicited antibody responses are pri-
marily type restricted to the genotypes covered.
Although limited partial cross protection has been
observed against homologous HPV genotypes, the
duration of cross protection is unknown. L1 vac-
cines that contain VLPs for multiple HPV types
might broaden protection. Merck is recruiting for
phase III clinical trials of a nine-valent vaccine,
V503.6 Another promising method involves the L2
minor capsid protein, which is highly conserved
across HPV genotypes. Efforts have focused on
boosting the immunogenicity of L2 by linking
together short amino acid sequences of L2 from
different oncogenic HPV types.7 Although multi-
meric L2 has shown robust antibody responses
in preclinical models against multiple HPV types,
it is not as immunogenic as VLPs. Upon success-
fully finding an appropriate adjuvant, this ap-
proach will be explored in clinical trials.
Therapeutic HPV Vaccines
The existing global burden of HPV associated le-
sions and cervical cancer emphasize the urgent
need for therapeutic HPV vaccines. Current pre-
ventive vaccines exert no therapeutic effects and
it would take many years of mass vaccination to
reduce cervical cancer rates, because of the high
prevalence of HPV infection and the slow rate of
cervical carcinogenesis. In contrast to antibodies
induced by preventive vaccines, therapeutic vac-
cines aim to generate cell-mediated immune re-
sponses using killer T cells that actively destroy
HPV-infected cells. Hence, therapeutic vaccines can
exert immediate effects on lowering HPV-related
disease incidence.
Although definitive objectives have been
achieved in developing preventive HPV vaccines,
overall progress in therapeutic HPV vaccine devel-
opment has been slower. Vaccination to control
cervical cancer has been evaluated in several forms,
such as live vector-, peptide/protein-, nucleic acid-
and whole-cell-based therapeutic HPV vaccines
that target HPV E6 and E7 oncoproteins.8 The
promising preclinical data have led to the evalu-
ation of several therapeutic vaccine candidates in
early phase clinical trials.
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Long overlapping peptides have stirred enthu-
siasm for therapeutic HPV E6/E7 peptide-based
vaccines because they could limit the obstacle of
major histocompatibility complex restriction by
broadening the range of antigenic epitopes. A vac-
cine comprised of 13 overlapping peptides that
represents HPV-16 E6 and E7, formulated in Mon-
tanide ISA 51 adjuvant, has been shown to be safe
and well tolerated in earlier trials, and has most
recently demonstrated great efficacy in a phase II
trial, thus leading to complete clinical responses in
nine of 19 patients with evaluable HPV-16-positive,
high-grade, vulvar intraepithelial neoplasms.9
DNA vaccines that employ strategies to enhance
vaccine potency have also stimulated great interest.
Microencapsulation of DNA vaccines can prevent
DNA degradation by nucleases, for efficient deliv-
ery. Amolimogene bepiplasmid (ZYC101A), a DNA
vaccine comprised of plasmid DNA that encodes
HPV 16/18 E6/E7 proteins encapsulated in poly
(glycolide-lactide) biopolymer, has advanced to
phase II/III clinical trials and is undergoing in-
vestigation in CIN 2/3 patients.10 Other vaccine
potentiating approaches include intracellular tar-
geting strategies that utilize the understanding of
antigen processing/presentation pathways. One ex-
ample is Sig/E7(detox)/Hsp70, a DNA vaccine that
encodes a signal sequence for the endoplasmic
reticulum that is linked to an attenuated form of
HPV-16 E7 and fused to immunostimulatory
Hsp70. A phase I clinical trial of Sig/E7(detox)/
Hsp70 boosted with recombinant vaccinia virus
that encodes HPV-16/18 E6/E7 fusion protein (TA-
HPV), with or without imiquimod, is in progress in
CIN 2/3 patients.11 Additionally, a phase I trial has
recently begun to evaluate CRT/E7 (detox), a DNA
vaccine that encodes modified HPV-16 E7 linked
to calreticulin, delivered via a clinical grade gene
gun, in patients with high-grade CIN (oral com-
munication with Dr W Huh, November 2009).
Future Outlook
Although it is clear that HPV vaccines will not elim-
inate the need for effective cervical screening and
treatment for many years to come, they can sub-
stantially reduce the burden that cervical cancer im-
poses on women and health services in the long
run. Although significant challenges remain in
achieving broad coverage of adolescents and reduc-
ing the cost of these vaccines, the implementation
of two commercial preventive HPV vaccines has ex-
citing prospects. Additionally, with continuing
progress into the advanced stages of clinical trials
and further exploration of combinatorial strategies,
there is great promise for significant advances in the
field of therapeutic HPV vaccine development.
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